Company

Lumosa Therapeutics Co. Ltd

Headquarters: Taipei, Taiwan

Employees: 46

CEO: Mr. Rong-Jin Lin Ph.D.

TWSE: 6535

Market Cap

TW$41.01 Billion

TWD as of July 1, 2024

US$1.26 Billion

Market Cap History

Lumosa Therapeutics Co. Ltd market capitalization over time

Evolution of Lumosa Therapeutics Co. Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Lumosa Therapeutics Co. Ltd

Detailed Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Lumosa Therapeutics Co. Ltd has the following listings and related stock indices.


Stock: TWSE: 6535 wb_incandescent

Details

Headquarters:

No. 3-2, Park Street

4th Floor Nangang District

Taipei, 11503

Taiwan

Phone: 886 2 2655 7918

Fax: 886 2 2655 7919